MX9504802A - Anticuerpos anti-egfr y fvs de cadena simple anti-egfr. - Google Patents

Anticuerpos anti-egfr y fvs de cadena simple anti-egfr.

Info

Publication number
MX9504802A
MX9504802A MX9504802A MX9504802A MX9504802A MX 9504802 A MX9504802 A MX 9504802A MX 9504802 A MX9504802 A MX 9504802A MX 9504802 A MX9504802 A MX 9504802A MX 9504802 A MX9504802 A MX 9504802A
Authority
MX
Mexico
Prior art keywords
chain fvs
egfr
egfr antibodies
phage
antibody libraries
Prior art date
Application number
MX9504802A
Other languages
English (en)
Inventor
A Cathrine Kettleborough
Mary M Bendig
Keith H Ansell
Detlef Gussow
Jaume Adan
Francesc Mitjans
Elisabeth Rosell
Francesc Blasco
Jaume Piulats
Original Assignee
Merck Patent Gmbh
Haftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh, Haftung filed Critical Merck Patent Gmbh
Publication of MX9504802A publication Critical patent/MX9504802A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invencion se relaciona con anticuerpos anti-EGFR novedosos y Fvs de cadena simple (scFvs) de los mismos los cuales pueden obtenerse a partir de bibliotecas de anticuerpo de fago construidas a partir de células de un mamífero inmunizado, preferiblemente un raton. Dos de los Fvs de cadena simple aislados de las bibliotecas de anticuerpo de fago se diseñaron para crear moléculas de anticuerpo completo parcialmente humanizadas. Esos anticuerpos anti-EGFR quiméricos contienen regiones constantes de inmunoglobulinas humanas y pueden utilizarse también como el Fvs de cadena simple como agente para el diagnostico y terapia de tumores humanos.
MX9504802A 1994-03-17 1995-03-16 Anticuerpos anti-egfr y fvs de cadena simple anti-egfr. MX9504802A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP94104160 1994-03-17
EP94118970 1994-12-02
PCT/EP1995/000978 WO1995025167A1 (en) 1994-03-17 1995-03-16 Anti-egfr single-chain fvs and anti-egfr antibodies

Publications (1)

Publication Number Publication Date
MX9504802A true MX9504802A (es) 1997-05-31

Family

ID=26135522

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9504802A MX9504802A (es) 1994-03-17 1995-03-16 Anticuerpos anti-egfr y fvs de cadena simple anti-egfr.

Country Status (20)

Country Link
US (1) US5844093A (es)
EP (1) EP0699237B1 (es)
JP (2) JPH08510922A (es)
KR (1) KR100376038B1 (es)
AT (1) ATE232902T1 (es)
AU (1) AU2071695A (es)
CA (1) CA2163012C (es)
CZ (1) CZ292061B6 (es)
DE (1) DE69529649T2 (es)
DK (1) DK0699237T3 (es)
ES (1) ES2191702T3 (es)
HU (1) HU221001B1 (es)
MX (1) MX9504802A (es)
NO (1) NO322252B1 (es)
PL (1) PL181342B1 (es)
PT (1) PT699237E (es)
RU (1) RU2170257C2 (es)
SK (1) SK283889B6 (es)
UA (1) UA41929C2 (es)
WO (1) WO1995025167A1 (es)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0659439B1 (en) 1993-12-24 2001-10-24 MERCK PATENT GmbH Immunoconjugates
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
WO1998012227A1 (en) * 1996-09-19 1998-03-26 Diagnocure Inc. Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof
EP2305027B1 (en) * 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
CN1276830A (zh) 1997-09-02 2000-12-13 住友制药株式会社 抗乙型肝炎病毒核心蛋白的单链抗体及其基因和含有它们的乙型肝炎治疗药物
DE19744531A1 (de) * 1997-10-09 1999-05-27 Klaus Dr Rer Nat Bosslet Bindemoleküle gegen Rezeptor-Ligand-Komplexe
PT1032660E (pt) 1997-11-17 2009-12-28 Micromet Ag Processo de identificação dos domínios do sítio de ligação que retêm a capacidade de ligação a um epítope
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
ATE217889T1 (de) 1998-08-28 2002-06-15 Genentech Inc Humane antikörper gegen faktor ix/ixa
HK1047236A1 (zh) * 1999-05-14 2003-02-14 Imclone Llc 用表皮生长因子受体拮抗剂治疗难治的人肿瘤
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
US6790631B1 (en) * 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
US7361338B2 (en) * 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
BR0110927A (pt) * 2000-05-19 2003-03-11 Scancell Ltd Anticorpo, ácido nucléico, vetor, célula, método de fabricar um anticorpo, composição farmacêutica, uso de um anticorpo ou de um ácido nucleico, e, método para o tratamento ou profilaxia do câncer
EP1314740A4 (en) * 2000-06-14 2005-01-19 Med & Biological Lab Co Ltd PREPARATION METHODS OF FLUORESCENCE PROTEIN FUSIONED SCFV ANTIBODIES
US7598055B2 (en) * 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
AU2001276842B2 (en) * 2000-06-28 2007-04-26 Glycofi, Inc. Methods for producing modified glycoproteins
US8697394B2 (en) 2000-06-28 2014-04-15 Glycofi, Inc. Production of modified glycoproteins having multiple antennary structures
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
JP2004527456A (ja) * 2000-08-09 2004-09-09 イムクローン システムズ インコーポレイティド Ｅｇｆ受容体拮抗剤による過増殖性の疾患の治療
AU2001288342A1 (en) * 2000-08-21 2002-03-04 Smith Kline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CA2433877C (en) * 2001-01-17 2014-11-18 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
GB0103389D0 (en) * 2001-02-12 2001-03-28 Novartis Ag Organic compounds
DE60232785D1 (de) 2001-03-14 2009-08-13 Myriad Genetics Inc Tsg101-gag-wechselwirkung und ihre verwendung
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
DE60234094D1 (de) 2001-05-11 2009-12-03 Ludwig Inst For Cancer Res Ltd Spezifische bindungsproteine und ihre verwendung
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US20020193569A1 (en) * 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
JP4298498B2 (ja) * 2001-06-13 2009-07-22 ゲンマブ エー／エス 上皮成長因子受容体（ｅｇｆｒ）に対するヒトモノクローナル抗体
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
JP2006506317A (ja) 2002-01-11 2006-02-23 バイオマリン ファーマシューティカル インコーポレイテッド 治療用リソソーム酵素の送達のための酵素送達系としてのｐ９７の使用
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
US8034904B2 (en) * 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
EP2263691B1 (en) 2002-07-15 2012-08-29 F.Hoffmann-La Roche Ag Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4)
PT1565478T (pt) 2002-11-12 2017-11-14 The Brigham And Women`S Hospital Inc Vacina de polissacáridos para infeções estafilocócicas
US20040147428A1 (en) * 2002-11-15 2004-07-29 Pluenneke John D. Methods of treatment using an inhibitor of epidermal growth factor receptor
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
EP1622941A2 (en) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
ATE485307T1 (de) 2003-11-07 2010-11-15 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
PT1735348E (pt) * 2004-03-19 2012-07-24 Imclone Llc Anticorpo anti-receptor do factor de crescimento humano
EP2468769A1 (en) 2004-04-21 2012-06-27 The Brigham and Women's Hospital, Inc. Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof
GB0410627D0 (en) * 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
ES2460517T3 (es) 2005-07-25 2014-05-13 Emergent Product Development Seattle, Llc Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20
JP2009518024A (ja) * 2005-12-06 2009-05-07 ドマンティス リミテッド Ｅｇｆｒおよび／またはｖｅｇｆに対して結合特異性を有するリガンドおよびその使用法
US7503217B2 (en) * 2006-01-27 2009-03-17 Weatherford/Lamb, Inc. Sonar sand detection
US8173374B2 (en) 2006-03-06 2012-05-08 Agency For Science, Technology And Research Human embryonic stem cell methods and PODXL expression
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
EP2078732B1 (en) 2006-07-10 2015-09-16 Fujita Health University Method of identifying a candidate diagnostic or therapeutic antibody using flow cytometry
CA2672120A1 (en) 2006-12-07 2008-06-12 Novartis Ag Antagonistic antibodies against ephb3
EP2094303A1 (en) * 2006-12-22 2009-09-02 Novelix Therapeutics Gmbh Treatment of diabetes by at least one epidermal growth factor receptor specific antibody or a derivative thereof
CA2676244C (en) 2007-01-25 2017-01-17 Kwok-Kin Wong Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
CN101688229B (zh) 2007-03-15 2013-06-12 路德维格癌症研究所 包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途
US20100322939A1 (en) * 2007-06-21 2010-12-23 Genmab A/S Novel methods for treating egfr-associated tumors
CA2696360C (en) 2007-08-14 2018-11-20 Ludwig Institute For Cancer Research Monoclonal antibody targeting the egfr receptor and uses thereof
CN101868246A (zh) 2007-09-21 2010-10-20 加利福尼亚大学董事会 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
PT2132228E (pt) * 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
AR072000A1 (es) 2008-06-03 2010-07-28 Abbott Lab Proteinas de union multivalentes con capacidad de unir dos o mas antigenos y usos de la misma
JP2011523853A (ja) 2008-06-03 2011-08-25 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリン及びその使用
BRPI0915448A2 (pt) 2008-07-08 2015-11-10 Abbott Lab imunoglobulinas de domínio variável duplo para prostaglandina e2 e usos das mesmas
KR20150041178A (ko) 2008-07-21 2015-04-15 더 브리검 앤드 우먼즈 하스피털, 인크. 합성 베타-1,6 글루코사민 올리고당에 관한 방법 및 조성물
KR101108642B1 (ko) * 2009-09-29 2012-02-09 주식회사 녹십자 표피 성장 인자 수용체에 특이적으로 결합하는 항체
TW201119676A (en) 2009-10-15 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US20120282274A1 (en) * 2009-11-20 2012-11-08 Northshore University Health System Research Institute Targeting of the c-terminal segment of c.difficile toxin b for improved clinical diagnosis, prevention, and treatment
MX2012006406A (es) 2009-12-04 2012-07-25 Genentech Inc Anticuerpos multiespecificos, analogos de anticuerpo, composiciones y metodos.
CN102167743B (zh) * 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗egfr单克隆抗体、其制备方法及用途
US9637557B2 (en) 2010-04-23 2017-05-02 Genentech, Inc. Production of heteromultimeric proteins
US9029513B2 (en) 2010-06-04 2015-05-12 Toagosei Co. Ltd. Anti-EGFR antibody and use thereof
EP3252072A3 (en) 2010-08-03 2018-03-14 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
SG187938A1 (en) 2010-08-26 2013-04-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
KR101273918B1 (ko) * 2010-09-17 2013-06-13 강원대학교산학협력단 인간 항-상피세포성 성장인자수용체 Ｆａｂ 항체 및 이를 포함하는 종양 치료용 약학 조성물
AU2011320318B9 (en) 2010-10-29 2015-11-19 Immunogen, Inc. Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
US8790649B2 (en) 2010-10-29 2014-07-29 Immunogen, Inc. EGFR-binding molecules and immunoconjugates thereof
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
CN103649117B (zh) 2011-02-04 2016-09-14 霍夫曼-拉罗奇有限公司 Fc变体及其生成方法
US9402916B2 (en) 2011-03-17 2016-08-02 The University Of Birmingham Re-directed immunotherapy
AU2012278944B2 (en) 2011-07-05 2015-09-17 Bioasis Technologies Inc. p97-antibody conjugates and methods of use
EP2739649B1 (en) 2011-08-05 2017-09-27 Bioasis Technologies Inc. P97 fragments with transfer activity
CA2849508C (en) 2011-09-30 2020-12-22 Regeneron Pharmaceuticals, Inc. Anti-erbb3 antibodies and uses thereof
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
EP3559049B1 (en) 2011-10-28 2025-06-11 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
KR20140105765A (ko) 2011-11-21 2014-09-02 이뮤노젠 아이엔씨 EGfr 항체 세포독성제 접합체에 의한 EGfr 치료에 내성을 나타내는 종양의 치료 방법
CN104159920A (zh) 2011-12-30 2014-11-19 艾伯维公司 针对il-13和/或il-17的双重可变结构域免疫球蛋白
CA2866933C (en) 2012-03-21 2020-08-18 Rheinisch-Westfalische Technische Hochschule Aachen Novel photoimmunoconjugates for use in photodynamic therapy
WO2013173255A2 (en) 2012-05-17 2013-11-21 Sorrento Therapeutics Inc. Antigen binding proteins that bind egfr
TW201843172A (zh) 2012-06-25 2018-12-16 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
CN104662150B (zh) 2012-07-31 2018-07-10 比奥阿赛斯技术有限公司 脱磷酸化的溶酶体贮积症蛋白及其使用方法
MY171664A (en) 2012-11-01 2019-10-22 Abbvie Inc Anti-dll4/vegf dual variable domain immunoglobulins and uses thereof
JP6586412B2 (ja) 2013-03-13 2019-10-02 バイオアシス テクノロジーズ インコーポレイテッド ｐ９７のフラグメントおよびその使用
JP2016522793A (ja) 2013-03-15 2016-08-04 アッヴィ・インコーポレイテッド ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
FI3677591T3 (fi) 2013-04-29 2023-04-03 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38-vasta-aineet ja fuusiot heikennetylle interferonille alfa-2b
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
ES2764973T3 (es) 2014-02-03 2020-06-05 Bioasis Technologies Inc Proteínas de fusión de P97
ES2762672T3 (es) 2014-02-19 2020-05-25 Bioasis Technologies Inc Proteínas de fusión de P97-IDS
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
WO2015168521A2 (en) 2014-05-01 2015-11-05 Bioasis Technologies, Inc. P97-polynucleotide conjugates
HUE063273T2 (hu) 2014-05-06 2024-01-28 Hoffmann La Roche Heteromultimer fehérjék elõállítása emlõssejtek felhasználásával
JP5924795B2 (ja) 2014-06-13 2016-05-25 テンボロン オイ 複合体
EA037749B1 (ru) 2014-10-29 2021-05-18 Тева Фармасьютикалз Острэйлиа Пти Лтд ВАРИАНТЫ ИНТЕРФЕРОНА 2b
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
ES2889906T3 (es) 2015-05-21 2022-01-14 Harpoon Therapeutics Inc Proteínas de unión triespecíficas y usos médicos
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
MX2018003292A (es) 2015-09-21 2018-08-01 Aptevo Res & Development Llc Polipéptidos de unión a cd3.
CA3024723A1 (en) 2016-05-20 2017-11-23 Robert B. Dubridge Single domain serum albumin binding protein
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
JP7241677B2 (ja) 2016-07-19 2023-03-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ４７併用療法
CN110300603B (zh) * 2017-02-14 2023-04-14 亘喜生物科技（上海）有限公司 Cd47-car-t细胞
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
BR112019023855B1 (pt) 2017-05-12 2021-11-30 Harpoon Therapeutics, Inc Proteínas de ligação à mesotelina
WO2018218633A1 (en) 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
JP7084990B2 (ja) 2017-10-13 2022-06-15 ハープーン セラピューティクス，インク． 三重特異性タンパク質と使用方法
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
CN109879964B (zh) * 2017-12-06 2022-08-05 北京科立思维生物科技有限公司 抗egfr单链抗体、抗pd1单链抗体及融合蛋白
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
WO2019222283A1 (en) 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Binding moiety for conditional activation of immunoglobulin molecules
KR20210044251A (ko) 2018-08-13 2021-04-22 베이징 페르칸스 온콜로지 컴퍼니 리미티드 암 치료용 바이오마커
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN113286817B (zh) 2018-09-25 2025-01-28 哈普恩治疗公司 Dll3结合蛋白及使用方法
AU2019370276A1 (en) 2018-10-30 2021-06-10 Board Of Regents, The University Of Texas System Anti-CD79b antibodies and chimeric antigen receptors and methods of use thereof
CA3120800A1 (en) 2018-12-17 2020-06-25 Revitope Limited Twin immune cell engager
US12397014B2 (en) 2019-02-05 2025-08-26 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
US12516128B2 (en) 2019-05-14 2026-01-06 Harpoon Therapeutics, Inc. EpCAM binding proteins and methods of use
KR20230003580A (ko) * 2020-04-30 2023-01-06 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 항-cd79b 항체 및 키메라 항원 수용체 및 이의 사용 방법
CA3128035A1 (en) 2020-08-13 2022-02-13 Bioasis Technologies, Inc. Combination therapies for delivery across the blood brain barrier
AU2021357841A1 (en) 2020-10-08 2023-06-15 Affimed Gmbh Trispecific binders
JP2024529381A (ja) 2021-07-30 2024-08-06 アフィメド ゲーエムベーハー デュプレックスボディ
KR20240099382A (ko) 2021-11-03 2024-06-28 아피메트 게엠베하 이중특이적 cd16a 결합제
WO2025257588A1 (en) 2024-06-10 2025-12-18 Affimed Gmbh Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance
CN119101160B (zh) * 2024-10-25 2025-02-11 江苏百英生物科技有限公司 一种抗cd28纳米抗体、基于天然库筛选cd28纳米抗体的方法及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2016842A1 (en) * 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
US5395750A (en) * 1992-02-28 1995-03-07 Hoffmann-La Roche Inc. Methods for producing proteins which bind to predetermined antigens
IT1271461B (it) * 1993-12-01 1997-05-28 Menarini Ricerche Sud Spa Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso.
GB9401182D0 (en) * 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect

Also Published As

Publication number Publication date
NO322252B1 (no) 2006-09-04
HU9503285D0 (en) 1996-02-28
ATE232902T1 (de) 2003-03-15
DE69529649D1 (de) 2003-03-27
NO954626D0 (no) 1995-11-16
CA2163012C (en) 2009-12-08
UA41929C2 (uk) 2001-10-15
AU2071695A (en) 1995-10-03
RU2170257C2 (ru) 2001-07-10
JPH08510922A (ja) 1996-11-19
SK143095A3 (en) 1996-11-06
HUT73461A (en) 1996-08-28
PL311661A1 (en) 1996-03-04
EP0699237B1 (en) 2003-02-19
PL181342B1 (pl) 2001-07-31
NO954626L (no) 1995-11-16
US5844093A (en) 1998-12-01
DE69529649T2 (de) 2003-12-18
CA2163012A1 (en) 1995-09-21
KR100376038B1 (ko) 2003-06-09
SK283889B6 (sk) 2004-04-06
WO1995025167A1 (en) 1995-09-21
DK0699237T3 (da) 2003-05-26
CZ301495A3 (en) 1996-02-14
PT699237E (pt) 2003-07-31
HU221001B1 (hu) 2002-07-29
ES2191702T3 (es) 2003-09-16
JP2006025794A (ja) 2006-02-02
EP0699237A1 (en) 1996-03-06
CZ292061B6 (cs) 2003-07-16

Similar Documents

Publication Publication Date Title
MX9504802A (es) Anticuerpos anti-egfr y fvs de cadena simple anti-egfr.
CN101970497B (zh) 抗‑EpCAM抗体及其用途
US9409976B2 (en) CDIM binding proteins and uses thereof
Maleki et al. Future prospects of monoclonal antibodies as magic bullets in immunotherapy
HUP0101160A2 (hu) Humán szöveti faktor (TF) elleni humanizált antitest és eljárás előállítására
BRPI0316779B1 (pt) anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados
WO1997002479A3 (en) Human monoclonal anti-tumor antibodies
GEP20074222B (en) Antibodies to cd40
ATE208820T1 (de) Humanisierte antikoerper
NO942912L (no) Konstruksjon, kloning og ekspresjon av humaniserte, monoklonale antistoffer mot humant interleukin-5
HUT65687A (en) Humanized and chimaeric monoclonal antibodies comprising of them pharmaceutical composition and the antibodies coding sequence containing of expression vectors, and process for the praparation of antibodies
DK0586002T3 (da) Monoklonale antistoffer, som genkender epidermisvækstfaktor-receptoren, celler og fremgangsmåder heraf og præparater indeho
MD1374G2 (ro) Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică
MY137078A (en) Recombinant antibodies associated to gangliosides. their use indiagnosis and treatment of tumors.
Pereira et al. A model system for detection and isolation of a tumor cell surface antigen using antibody phage display
CA2012993A1 (en) Monoclonal antibodies (mabs) against tumor-associated antigens, the preparation and use thereof
ZA202302392B (en) Antibodies against ilt2 and use thereof
SG146644A1 (en) Kid3 and kid3 antibodies that bind thereto
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
WO2021254574A3 (en) Cd38 antibodies for the treatment of human diseases
WO2023202672A9 (en) Antibodies targeting sirp-alpha and uses thereof
Asano et al. Application of the Fc fusion format to generate tag‐free bi‐specific diabodies
EP0155172A3 (en) Anti-human lung cancer monoclonal antibodies
WO2023177974A3 (en) Anti-mesothelin antibodies and uses thereof
WO2022015716A3 (en) Novel anti-pd1 antibodies for inhibiting t-cell activity

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees